Register entry
Regeneron Pharmaceuticals, Inc.
- Registered sites
- 3
- Drug products
- 30
- Live patents
- 0
- Countries
- 2
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingActive ingredient (API) manufactureLabellingFinished drug manufacturePackagingRelabellingRepackagingsterilize
Sites
Facilities
3| Site | Location | Operations | FEI |
|---|---|---|---|
| REGENERON IRELAND DESIGNATED ACTIVITY COMPANY | Raheen Business ParkIreland | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3011684330 |
| Regeneron Pharmaceuticals, Inc. | East Greenbush, NYUnited States | Analytical testing, Labelling, Finished drug manufacture, Packaging, Relabelling, Repackaging, sterilize | 3015581066 |
| Regeneron Pharmaceuticals, Inc. | Rensselaer, NYUnited States | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 1000514603 |
Catalogue
Marketed products
30Showing 30 of 30.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| - | Alirocumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | Dupilumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | Dupilumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| EYLEA | aflibercept | INJECTION, SOLUTION | BLA |
| EYLEA HD | aflibercept | INJECTION, SOLUTION | BLA |
| EYLEA HD | aflibercept | INJECTION, SOLUTION | BLA |
| - | Evinacumab | SOLUTION | DRUG FOR FURTHER PROCESSING |
| Inmazeb | atoltivimab, maftivimab, and odesivimab-ebgn | INJECTION, SOLUTION | BLA |
| Inmazeb | atoltivimab, maftivimab, and odesivimab-ebgn | INJECTION, SOLUTION | BLA |
| LIBTAYO | cemiplimab-rwlc | INJECTION | BLA |
| OTARMENI | lunsotogene parvec-cwha | INJECTION, SOLUTION | BLA |
| - | Pozelimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| Praluent | alirocumab | INJECTION, SOLUTION | BLA |
| Praluent | alirocumab | INJECTION, SOLUTION | BLA |
| - | Sarilumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | Sarilumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| VEOPOZ | Pozelimab | INJECTION, SOLUTION | BLA |
| - | aflibercept | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | aflibercept | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | aflibercept | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | atoltivimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | atoltivimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | cemiplimab | SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | cemiplimab | SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | linvoseltamab | SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | maftivimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | maftivimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | odesivimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | odesivimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | rilonacept | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | DRUG FOR FURTHER PROCESSING |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.